Barclays Reiterates “$54.00” Price Target for Pfizer (NYSE:PFE)

Barclays set a $54.00 price objective on Pfizer (NYSE:PFE) in a research report sent to investors on Tuesday morning, Borsen Zeitung reports.

Several other equities research analysts also recently weighed in on the stock. Cantor Fitzgerald reaffirmed a buy rating and set a $60.00 target price on shares of Pfizer in a research note on Friday, November 5th. Sanford C. Bernstein boosted their price target on shares of Pfizer from $44.00 to $65.00 and gave the stock a market perform rating in a report on Monday, January 3rd. Truist Securities boosted their price target on shares of Pfizer from $43.00 to $58.00 and gave the stock a buy rating in a report on Wednesday, November 24th. Morgan Stanley upped their target price on shares of Pfizer from $50.00 to $60.00 and gave the company an equal weight rating in a report on Monday, November 29th. Finally, Berenberg Bank restated a hold rating and issued a $54.00 target price on shares of Pfizer in a report on Tuesday, December 14th. Nine research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of Buy and an average price target of $57.81.

PFE opened at $54.95 on Tuesday. The firm has a market capitalization of $308.43 billion, a PE ratio of 16.35, a PEG ratio of 0.76 and a beta of 0.69. Pfizer has a twelve month low of $33.36 and a twelve month high of $61.71. The firm’s 50-day moving average price is $54.39 and its 200 day moving average price is $47.49. The company has a current ratio of 1.39, a quick ratio of 1.18 and a debt-to-equity ratio of 0.48.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 2nd. The biopharmaceutical company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.26. Pfizer had a net margin of 27.66% and a return on equity of 30.70%. The firm had revenue of $24.09 billion for the quarter, compared to analyst estimates of $22.82 billion. During the same period in the previous year, the business posted $0.72 earnings per share. Pfizer’s quarterly revenue was up 134.4% on a year-over-year basis. As a group, analysts predict that Pfizer will post 4.18 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 4th. Stockholders of record on Friday, January 28th will be paid a dividend of $0.40 per share. The ex-dividend date is Thursday, January 27th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.91%. This is a positive change from Pfizer’s previous quarterly dividend of $0.39. Pfizer’s dividend payout ratio (DPR) is currently 46.43%.

In related news, EVP Douglas M. Lankler sold 40,000 shares of Pfizer stock in a transaction on Friday, November 26th. The shares were sold at an average price of $54.37, for a total value of $2,174,800.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John D. Young sold 150,000 shares of Pfizer stock in a transaction on Thursday, November 11th. The stock was sold at an average price of $50.06, for a total transaction of $7,509,000.00. The disclosure for this sale can be found here. Insiders have sold 231,360 shares of company stock worth $11,927,994 in the last quarter. Insiders own 0.05% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the business. Ibex Wealth Advisors acquired a new position in shares of Pfizer during the third quarter valued at $26,000. Core Alternative Capital acquired a new position in shares of Pfizer during the third quarter valued at $30,000. Kozak & Associates Inc. acquired a new position in shares of Pfizer during the third quarter valued at $46,000. GoalVest Advisory LLC acquired a new position in shares of Pfizer during the second quarter valued at $39,000. Finally, Tower View Investment Management & Research LLC acquired a new position in shares of Pfizer during the third quarter valued at $43,000. 64.88% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Further Reading: What sectors are represented in the Hang Seng index?

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.